Cargando…
The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan
Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, guidance (“Japanese Guide”) has been published by a working group of several academic societies and announced by the Ministry of Health, Labour, and Welfare. Steroids as a candidate treatment for COVID-19 were noted in the Japan...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239045/ https://www.ncbi.nlm.nih.gov/pubmed/37270639 http://dx.doi.org/10.1038/s41598-023-36199-w |
_version_ | 1785053416145289216 |
---|---|
author | Higuchi, Takuya Shin, Jung-ho Takada, Daisuke Morishita, Tetsuji Kunisawa, Susumu Imanaka, Yuichi |
author_facet | Higuchi, Takuya Shin, Jung-ho Takada, Daisuke Morishita, Tetsuji Kunisawa, Susumu Imanaka, Yuichi |
author_sort | Higuchi, Takuya |
collection | PubMed |
description | Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, guidance (“Japanese Guide”) has been published by a working group of several academic societies and announced by the Ministry of Health, Labour, and Welfare. Steroids as a candidate treatment for COVID-19 were noted in the Japanese Guide. However, the prescription details for steroids, and whether the Japanese Guide changed its clinical practice, were unclear. This study aimed to examine the impact of the Japanese Guide on the trends in the prescription of steroids for COVID-19 inpatients in Japan. We selected our study population using Diagnostic Procedure Combination (DPC) data from hospitals participating in the Quality Indicator/Improvement Project (QIP). The inclusion criteria were patients discharged from hospital between January 2020 and December 2020, who had been diagnosed with COVID-19, and were aged 18 years or older. The epidemiological characteristics of cases and the proportion of steroid prescriptions were described on a weekly basis. The same analysis was performed for subgroups classified by disease severity. The study population comprised 8603 cases (410 severe cases, 2231 moderate II cases, and 5962 moderate I/mild cases). The maximum proportion of cases prescribed with dexamethasone increased remarkably from 2.5 to 35.2% in the study population before and after week 29 (July 2020), when dexamethasone was included in the guidance. These increases were 7.7% to 58.7% in severe cases, 5.0% to 57.2% in moderate II cases, and 1.1% to 19.2% in moderate I/mild cases. Although the proportion of cases prescribed prednisolone and methylprednisolone decreased in moderate II and moderate I/mild cases, it remained high in severe cases. We showed the trends of steroid prescriptions in COVID-19 inpatients. The results showed that guidance can influence drug treatment provided during an emerging infectious disease pandemic. |
format | Online Article Text |
id | pubmed-10239045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-102390452023-06-05 The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan Higuchi, Takuya Shin, Jung-ho Takada, Daisuke Morishita, Tetsuji Kunisawa, Susumu Imanaka, Yuichi Sci Rep Article Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, guidance (“Japanese Guide”) has been published by a working group of several academic societies and announced by the Ministry of Health, Labour, and Welfare. Steroids as a candidate treatment for COVID-19 were noted in the Japanese Guide. However, the prescription details for steroids, and whether the Japanese Guide changed its clinical practice, were unclear. This study aimed to examine the impact of the Japanese Guide on the trends in the prescription of steroids for COVID-19 inpatients in Japan. We selected our study population using Diagnostic Procedure Combination (DPC) data from hospitals participating in the Quality Indicator/Improvement Project (QIP). The inclusion criteria were patients discharged from hospital between January 2020 and December 2020, who had been diagnosed with COVID-19, and were aged 18 years or older. The epidemiological characteristics of cases and the proportion of steroid prescriptions were described on a weekly basis. The same analysis was performed for subgroups classified by disease severity. The study population comprised 8603 cases (410 severe cases, 2231 moderate II cases, and 5962 moderate I/mild cases). The maximum proportion of cases prescribed with dexamethasone increased remarkably from 2.5 to 35.2% in the study population before and after week 29 (July 2020), when dexamethasone was included in the guidance. These increases were 7.7% to 58.7% in severe cases, 5.0% to 57.2% in moderate II cases, and 1.1% to 19.2% in moderate I/mild cases. Although the proportion of cases prescribed prednisolone and methylprednisolone decreased in moderate II and moderate I/mild cases, it remained high in severe cases. We showed the trends of steroid prescriptions in COVID-19 inpatients. The results showed that guidance can influence drug treatment provided during an emerging infectious disease pandemic. Nature Publishing Group UK 2023-06-03 /pmc/articles/PMC10239045/ /pubmed/37270639 http://dx.doi.org/10.1038/s41598-023-36199-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Higuchi, Takuya Shin, Jung-ho Takada, Daisuke Morishita, Tetsuji Kunisawa, Susumu Imanaka, Yuichi The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan |
title | The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan |
title_full | The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan |
title_fullStr | The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan |
title_full_unstemmed | The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan |
title_short | The Japanese Guide affected the prescription of steroids for COVID-19 inpatients during the COVID-19 epidemic in Japan |
title_sort | japanese guide affected the prescription of steroids for covid-19 inpatients during the covid-19 epidemic in japan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239045/ https://www.ncbi.nlm.nih.gov/pubmed/37270639 http://dx.doi.org/10.1038/s41598-023-36199-w |
work_keys_str_mv | AT higuchitakuya thejapaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT shinjungho thejapaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT takadadaisuke thejapaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT morishitatetsuji thejapaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT kunisawasusumu thejapaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT imanakayuichi thejapaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT higuchitakuya japaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT shinjungho japaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT takadadaisuke japaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT morishitatetsuji japaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT kunisawasusumu japaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan AT imanakayuichi japaneseguideaffectedtheprescriptionofsteroidsforcovid19inpatientsduringthecovid19epidemicinjapan |